TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37019764

Group type: EXPERIMENTAL
Intervention: Avelumab + BSC
Number of subjects: 147

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 147
Study: 37019807

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 226
Study: 37019821

Group type: EXPERIMENTAL
Intervention: RhoA/Rho-kinase inhibitor (fasudil)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: COVID-19 arteries (no specific intervention mentioned)
Number of subjects: 37
Study: 37019892

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem-cells transduced with the Lenti-D lentiviral vector containing ABCD1 cDNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogeneic hematopoietic stem cell transplantation
Number of subjects: 0
Study: 37019987

Group type: EXPERIMENTAL
Intervention: CE-CT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-[
Number of subjects: 0
Study: 37020027

Group type: EXPERIMENTAL
Intervention: AI cardiac function assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sonographer cardiac function assessment
Number of subjects: 0
Study: 37020098

Group type: EXPERIMENTAL
Intervention: Pilot balloon palpation for cuff pressure assessment
Number of subjects: 208

Group type: COMPARATOR
Intervention: Endotracheal tube ID 6.0
Number of subjects: 208

Group type: COMPARATOR
Intervention: Endotracheal tube ID 8.0
Number of subjects: 208
Study: 37020172

Group type: EXPERIMENTAL
Intervention: Hood PPE (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard PPE (n = 20)
Number of subjects: 40
Study: 37020200

Group type: EXPERIMENTAL
Intervention: Non-governmental orphanage
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Governmental orphanage
Number of subjects: 156

Group type: COMPARATOR
Intervention: Parented school children
Number of subjects: 156
Study: 37020274

Group type: EXPERIMENTAL
Intervention: Meditators (Samyama program with vegan diet)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Household controls
Number of subjects: 288
Study: 37020278

Group type: EXPERIMENTAL
Intervention: Baseline pain severity
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Pain > 2 years of evolution
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Baseline pain interference
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Pain > 2 years
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Depression severity
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Occupational status as active worker
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Currently working
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 317
Study: 37020259

Group type: EXPERIMENTAL
Intervention: Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes
Number of subjects: 3269

Group type: EXPERIMENTAL
Intervention: Autoantibodies against type I IFN
Number of subjects: 3269

Group type: COMPARATOR
Intervention: SARS-CoV-2-infected individuals without pneumonia
Number of subjects: 3269
Study: 37020315

Group type: EXPERIMENTAL
Intervention: TIPS (transjugular intrahepatic portosystemic shunt)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of Care (terlipressin and albumin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 100
Study: 37020570

Group type: EXPERIMENTAL
Intervention: Nefecon plus Best Supportive Care (BSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 0
Study: 37020805

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) supplementation at 500 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37020837

Group type: EXPERIMENTAL
Intervention: Advanced Diagnostic Profiling (ADPro) substudy using novel functional imaging and physiological assessments
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Physiological assessments of pulmonary function including spirometry, bronchodilator reversibility, static lung volumes
Number of subjects: 180
Study: 37020840

Group type: EXPERIMENTAL
Intervention: 250 mg d-cycloserine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 37020926

Group type: EXPERIMENTAL
Intervention: Socazolimab (5 mg/kg) every three weeks, Carboplatin (AUC: 5) every three weeks, Etoposide (100 mg/m2) every three weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Socazolimab, Carboplatin, and Etoposide
Number of subjects: 20
Study: 37021137

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 26
Study: 37021164

Group type: EXPERIMENTAL
Intervention: Discharged home (intervention group)
Number of subjects: 3184

Group type: COMPARATOR
Intervention: Discharged elsewhere (control group)
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: Discharged home (intervention group) after confounding adjustment
Number of subjects: 3184

Group type: COMPARATOR
Intervention: Discharged elsewhere (control group) after confounding adjustment
Number of subjects: 3184
Study: 37021170

Group type: EXPERIMENTAL
Intervention: Standardized educational talk (SET) on intravenous thrombolysis (IVT)
Number of subjects: 0
Study: 37021189

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 3
Study: 37021284

Group type: EXPERIMENTAL
Intervention: Astrocyte-derived exosomes (ADEs) in the SCD group
Number of subjects: 125

Group type: COMPARATOR
Intervention: Plasma levels of IL-6, IL-8, and MCP-1
Number of subjects: 125
Study: 37021333

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root debridement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study: 37021342

Group type: EXPERIMENTAL
Intervention: High-Up NHR trajectory
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Rise of >5 bpm in weekly average NHR
Number of subjects: 1013
Study: 37021397

Group type: EXPERIMENTAL
Intervention: Alemtuzumab administered intravenously (IV)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Alemtuzumab administered subcutaneously (SC)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (both IV and SC)
Number of subjects: 42
Study: 37021527

Group type: EXPERIMENTAL
Intervention: Five doses of intrathecal methotrexate (MTX)
Number of subjects: 6716

Group type: COMPARATOR
Intervention: Three doses of intrathecal methotrexate (MTX)
Number of subjects: 6716
Study: 37021546

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol-coated haemostatic patch (patch group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no reinforcement)
Number of subjects: 64
Study: 37021629

Group type: EXPERIMENTAL
Intervention: Butylphthalide
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (100 mL 0.9% saline and oral simulation capsule)
Number of subjects: 99
Study: 37021692

Group type: EXPERIMENTAL
Intervention: Annual azithromycin distributions targeted to children aged 0-5 years
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Annual azithromycin distributions targeted to households with a child aged 0-5 years with clinically active trachoma
Number of subjects: 48

Group type: COMPARATOR
Intervention: Continued annual mass azithromycin distributions to the entire community
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cessation of treatment
Number of subjects: 48
Study: 37021699

Group type: EXPERIMENTAL
Intervention: Transportation assistance
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nutrition supplementation
Number of subjects: 24
Study: 37021807

Group type: EXPERIMENTAL
Intervention: 20g/day SQ-LNSs
Number of subjects: 2711
Study: 37021952

Group type: EXPERIMENTAL
Intervention: Prospective arm examining all consecutive patients referred for echocardiography with suspected or confirmed endocarditis, followed up over 12 months for adverse outcomes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appropriateness of requests for first-line echocardiographic imaging in exclusion of endocarditis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Role of other imaging modalities in the diagnosis of endocarditis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impact of a specialized endocarditis team on outcomes.
Number of subjects: 0
Study: 37022378

Group type: EXPERIMENTAL
Intervention: Third-generation cephalosporin
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 599
Study: 37022483

Group type: EXPERIMENTAL
Intervention: Early palliative care consultation within 2 weeks of registration, followed by follow-up visits every 2 weeks for the first month, then every 4 weeks until week 16.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Early palliative care consultation
Number of subjects: 40
Study: 37022502

Group type: EXPERIMENTAL
Intervention: Cognitive Restructuration Treatment Group (CRTG, n=13)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-structured interviews (PIG group, n=14)
Number of subjects: 27
Study: 37022569

Group type: EXPERIMENTAL
Intervention: Daratumumab IV administration (0.1 to 24 mg/kg)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Daratumumab SC administration (1200 and 1800 mg)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: QSS approximation
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Baseline M protein as a covariate
Number of subjects: 850
Study: 37022679

Group type: EXPERIMENTAL
Intervention: Targeted hypoglossal nerve stimulation (THN) activated at month 1
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (THN activated at month 4)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Targeted hypoglossal nerve stimulation (THN)
Number of subjects: 138
Study: 37022680

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Fitness Walking
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 328
Study: 37022682

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention
Number of subjects: 4407

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4407

Group type: EXPERIMENTAL
Intervention: CTC intervention
Number of subjects: 4407
Study: 37022687

Group type: EXPERIMENTAL
Intervention: SB3
Number of subjects: 538

Group type: COMPARATOR
Intervention: TRZ
Number of subjects: 538
Study: 37022702

Group type: EXPERIMENTAL
Intervention: Metastasis-directed therapy (MDT) with intermittent hormone therapy (combined therapy arm; n=43)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Hormone therapy only (n=44)
Number of subjects: 87
Study: 37022706

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (3 mg/kg IV every 2 weeks plus 1 mg/kg IV every 6 weeks)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Nivolumab (3 mg/kg IV every 2 weeks)
Number of subjects: 425
Study: 37022717

Group type: EXPERIMENTAL
Intervention: Cyclosporine solution, 0.1%, applied twice daily for 29 days
Number of subjects: 834

Group type: COMPARATOR
Intervention: Vehicle, applied twice daily for 29 days
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Cyclosporine solution, 0.1%
Number of subjects: 834

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 834
Study: 37022774

Group type: EXPERIMENTAL
Intervention: Atellica® IM High-Sensitivity Troponin I (hs-cTnI) assay with a threshold of <10 ng/L
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Atellica® IM High-Sensitivity Troponin I (hs-cTnI) assay
Number of subjects: 1171
Study: 37022784

Group type: EXPERIMENTAL
Intervention: Amivantamab
Number of subjects: 0
Study: 37022932

Group type: EXPERIMENTAL
Intervention: Total ankle replacement
Number of subjects: 303

Group type: COMPARATOR
Intervention: Ankle fusion
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Fixed-bearing total ankle replacement
Number of subjects: 303
Study: 37023031

Group type: EXPERIMENTAL
Intervention: Anesthesia-centered bundle focused on perioperative lung expansion
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 750
Study: 37023069

Group type: EXPERIMENTAL
Intervention: Functional cast (FC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Volar-flexion ulnar deviation cast (VFUDC)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of treatment
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Health-related quality of life measurement (15D)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Short version of Disabilities of arm, shoulder and hand score (QuickDASH)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 105
Study: 37023284

Group type: EXPERIMENTAL
Intervention: Higher proportion of network members engaging in regular cannabis and heavy alcohol use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher proportions of network members engaging in heavy alcohol use, regular cannabis use, or other drug use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher proportions of network members engaging in traditional practices
Number of subjects: 0
Study: 37023336

Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hesperidin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Silver Diamine Fluoride (SDF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 37023374

Group type: EXPERIMENTAL
Intervention: Peritumoral injection of 0.5% lidocaine, 7-10 minutes before surgery
Number of subjects: 1583

Group type: COMPARATOR
Intervention: Surgery without lidocaine
Number of subjects: 1583
Study: 37023398

Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicine
Number of subjects: 0
Study: 37023443

Group type: EXPERIMENTAL
Intervention: Health coach-supported mental health app
Number of subjects: 25
Study: 37023451

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52-mg Intrauterine Device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37023455

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52-mg intrauterine device (IUD)
Number of subjects: 105
Study: 37023457

Group type: EXPERIMENTAL
Intervention: Estetrol 15 mg and drospirenone 3 mg (24 hormone and four placebo pills regimen)
Number of subjects: 2837
Study: 37023659

Group type: EXPERIMENTAL
Intervention: Monthly cash payment of 300 Rand conditional on school enrollment of index young women
Number of subjects: 3568
Study: 37023660

Group type: EXPERIMENTAL
Intervention: Couples nutrition
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Mothers bundled nutrition and parenting
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Couples bundled nutrition and parenting
Number of subjects: 960

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Mothers nutrition
Number of subjects: 960
Study: 37023705

Group type: EXPERIMENTAL
Intervention: Ipatasertib 300 mg daily, carboplatin AUC2, paclitaxel 80 mg m-2 days 1, 8, and 15 every 28 days (Arm A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg daily, carboplatin AUC2 days 1, 8, and 15 every 28 days (Arm B)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ipatasertib 300 mg 21 days on 7 days off, capecitabine 750 mg m-2, twice a day, 7 days on 7 days off, atezolizumab 840 mg days 1 and 15 every 28 days (Arm C)
Number of subjects: 28
Study: 37023789

Group type: EXPERIMENTAL
Intervention: Mandatory split-dose bowel preparation (SDBP)
Number of subjects: 770

Group type: COMPARATOR
Intervention: Optional split-dose bowel preparation (SDBP)
Number of subjects: 770
Study: 37023858

Group type: EXPERIMENTAL
Intervention: Extended release buprenorphine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sublingual buprenorphine
Number of subjects: 13
Study: 37023945

Group type: EXPERIMENTAL
Intervention: Opioid analgesia
Number of subjects: 27
Study: 37023987

Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy in combination with Durvalumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37024247

Group type: EXPERIMENTAL
Intervention: dCBT (Sleepio)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study: 37024249

Group type: EXPERIMENTAL
Intervention: RMC-035 (1.3 or 0.65 mg/kg intravenous infusion, five doses based on presurgery estimated glomerular filtration rate)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: RMC-035
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 37024252

Group type: EXPERIMENTAL
Intervention: 3D-printed orthosis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional orthosis
Number of subjects: 20
Study: 37024268

Group type: EXPERIMENTAL
Intervention: Contralateral oblique (CLO) view at 50°±5°
Number of subjects: 393
Study: 37024277

Group type: EXPERIMENTAL
Intervention: BI 764198
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 37024298

Group type: EXPERIMENTAL
Intervention: Defibrillation attempts (1 to 6 attempts)
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: Defibrillation attempts (higher number of attempts)
Number of subjects: 1983
Study: 37024382

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation protocols for children with DKA
Number of subjects: 753
Study: 37024420

Group type: EXPERIMENTAL
Intervention: D-VMP (Daratumumab + Bortezomib 1.3 mg/m² + Melphalan + Prednisone)
Number of subjects: 220

Group type: COMPARATOR
Intervention: VMP (Bortezomib 1.3 mg/m² + Melphalan + Prednisone)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: D-VMP
Number of subjects: 220

Group type: COMPARATOR
Intervention: VMP
Number of subjects: 220
Study: 37024478

Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF injections (IVI) during COVID-19 lockdown
Number of subjects: 157

Group type: COMPARATOR
Intervention: Delayed or missed intravitreal anti-VEGF injections (IVI) during COVID-19 lockdown
Number of subjects: 157
Study: 37024506

Group type: EXPERIMENTAL
Intervention: Participation in the PBRN
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Age 40 years or older
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Moderate clinic size
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Large clinic size
Number of subjects: 152
Study: 37024520

Group type: EXPERIMENTAL
Intervention: WVT078 (anti-BCMA× anti-CD3 bispecific antibody) administered intravenously once weekly at doses of 48-250 µg/kg (n=26)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: WVT078 (anti-BCMA× anti-CD3 bispecific antibody)
Number of subjects: 33
Study: 37024596

Group type: EXPERIMENTAL
Intervention: Intermittent fasting plus early time-restricted eating (iTRE)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Calorie restriction (CR)
Number of subjects: 209
Study: 37024634

Group type: EXPERIMENTAL
Intervention: Strengthening Our Vows video intervention
Number of subjects: 580
Study: 37024811

Group type: EXPERIMENTAL
Intervention: Immunological substudy with scheduled blood samples until 12 months after LT
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Epidemiological substudy using nationwide hospital records
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Potential proof-of-concept for adoptive T cell therapy against CMV and VZV
Number of subjects: 500
Study: 37024830

Group type: EXPERIMENTAL
Intervention: Early integrated palliative care
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21
Study: 37024868

Group type: EXPERIMENTAL
Intervention: Cohort A (15 NF135-infected mosquito bites under mefloquine prophylaxis)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cohort B (5 NF135-infected mosquito bites and presumptive treatment with artemether/lumefantrine)
Number of subjects: 40
Study: 37024906

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 37024945

Group type: EXPERIMENTAL
Intervention: Audit and feedback
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Active learning
Number of subjects: 335
Study: 37024948

Group type: EXPERIMENTAL
Intervention: Migraineurs (CM and EM)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chronic migraine (CM)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nucleus accumbens (NAC) iron volume
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Iron deposition in NAC
Number of subjects: 200

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 200
Study: 37024961

Group type: EXPERIMENTAL
Intervention: ART readiness tool (27-item questionnaire)
Number of subjects: 454
Study: 37024966

Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy using balanced crystalloids
Number of subjects: 66
Study: 37025023

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 3493

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 3493
Study: 37025083

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 3581

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 3581
Study: 37025256

Group type: EXPERIMENTAL
Intervention: Esketamine plus oral antidepressant (AD)
Number of subjects: 252

Group type: COMPARATOR
Intervention: AD plus placebo
Number of subjects: 252
Study: 37025348

Group type: EXPERIMENTAL
Intervention: Skills Program for Awareness, Connectedness, and Empowerment (SPACE)
Number of subjects: 0
Study: 37025394

Group type: EXPERIMENTAL
Intervention: Small increase in serum creatinine (Scr) within 48 hours of hospitalization
Number of subjects: 19424

Group type: COMPARATOR
Intervention: Normal serum creatinine at hospitalization
Number of subjects: 19424
Study: 37025594

Group type: EXPERIMENTAL
Intervention: Walking football (WF) program plus usual care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Walking football (WF) program
Number of subjects: 50
Study: 37025684

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normal-weight unmatched patients
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 2
Study: 37025758

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg or 480 mg IV) administered for up to 2 years until progression, combined with SRS (15-21 Gy) delivered within 14 days after the first dose of nivolumab.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SRS (15-21 Gy) to all un-irradiated BM delivered within 14 days after the first dose of nivolumab.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nivolumab and SRS combination treatment.
Number of subjects: 26